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TCT-793
Metformin Impairs Endothelialization After Placement of Newer Generation
Drug Eluting Stents
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Hirokuni Akahori1, Kim Pachura2, Aloke V. Finn3
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Background: Metformin may delay endothelialization of drug eluting stents
(DES) due to convergent signaling at the mammalian target of rapamycin
(mTOR) pathway. We aim to assess whether metformin will continue to
adversely affect stent endothelialization despite improvements in newer generation
DES.
Methods: Rabbit iliac artery stenting with newer generation DES was performed
followed by 14 days of oral metformin or placebo treatment. Scanning electron
microscopy was used to assess stent endothelialization after sacriﬁce.
Results: In the metformin-treated group there was signiﬁcantly less endothelialization
compared to the placebo-treated group. Paclitaxel-eluting stents in placebo-treated
group had the least delay in endothelialization with signiﬁcantly greater delay in both
its metformin-treated counterpart and all –limus eluting stent groups (ﬁgure 1).
Representative scanning electron micrographs (15x) of 14-day paclitaxel eluting stents
(PES), everolimus- and zotarolimus-eluting stents (EES, ZES) in the presence or
absence of oral Metformin (100 mg/kg/day) treatment (ﬁgure 1A) with quantiﬁcation
shown (Figure 1B, groups under the line representing p < 0.05 compared with PES-
control with at least 4 animals per group).Conclusions: Metformin inhibited stent endothelialization in newer generation DES
likely through convergent and divergent mechanisms. By delaying stent endothelial-
ization, metformin may increase the risk for thrombotic complications after DES
placement.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrTCT-794
Intracoronary Infusion of Bone Marrow Mesenchymal Stem Cells in Acute
Myocardial Infarction- A Critical Challenge for Dosage-Related Efﬁcacy and
Safety
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Background: To date, there have been debates on the risk and efﬁcacy of bone
marrow mesenchymal stem cell (BMSC) therapy in patients with acute myocardial
infarction (AMI). This study aimed at testing whether BMSC intracoronary infusion
following revascularization has a beneﬁcial effect on the myocardium of AMI
patients. This study is registered with ChiCTR, number ChiCTR-TRC-08000080.
Methods: A single-blind, randomized multicenter trial was conducted in patients with
ST-elevation MI (STEMI, n¼43), (2008-2009). All the patients who had been
successfully reperfused within 12 hours were randomly assigned to receive an intra-
coronary infusion of BMSCs or optimum medical therapy after PCI. The primary
endpoint was the change in myocardial viability and perfusion within the infarcted
territory by 18-FDG/99mTc-sestamibi SPECT, and the change in global left
ventricular ejection fraction by 2D echocardiography.
Results: A mean of (3.080.52) x106 2nd passage MSCs were obtained from 80 ml
bone marrow after an average of 14.60.7 days in culture. BMSCs were transplanted
at an average of 17.10.6 days. Six months after cell transfer, myocardial viability
within the infarct area was improved in both groups compared with baseline, but
18-FDG SPECT showed no signiﬁcant difference between the BMSC and control
groups (4.0  0.4% 95%CI 3.1-4.9 vs. 3.2  0.5% 95%CI 2.1-4.3, P¼0.237).
Moreover, 99mTc-sestamibi SPECT demonstrated that myocardial perfusion within
the infarct area in patients receiving BMSCs did not differ from the control group
(4.40.5% 95%CI 3.2-5.5 vs. 3.90.6% 95%CI 2.6-5.2, P¼0.594). Similarly, LVEF
after 12, 24 months of followup also did not show any difference between the two
groups (12mon' LVEF: 4.50.7% 95%CI 3.0-6.1 vs. 3.20.7% 95%CI 1.7-4.6,
P¼0.182). In the BMSC group, one patient suffered a serious complication involving
coronary artery occlusion during the MSC injection procedure.
Conclusions: The clinical beneﬁts and the safety of intracoronary injection of
autologous BMSCs in acute STEMI patients need further investigation and
reevaluation.
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Pre-clinical analysis of safety and efﬁcacy of a new sirolimus eluting stent
compared with bare metal, everolimus and sirolimus eluting controls
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Background: As requested by the regulatory agencies, new drug-eluting stents (DES)
must be tested in animal models before conducting clinical trials. This study analyzes
the antiproliferative efﬁcacy and the safety proﬁle (vascular healing) of new sirolimus
eluting stents (SES) as compared with their bare metallic backbone, bare metal stents
(BMS) and 2 different commercial DES, one SES and one everolimus-eluting stent
(EES).
Methods: In 12 young domestic pigs (253 kg), 36 stents were implanted: 11 SES
Test1, 10 SES Test2 (iVascular, Spain), 5 SES Cypher (J&J, USA), 5 EES Xience
(Abbott, USA) and 5 control BMS Architect (iVascular, Spain). The achieved
stent:artery ratio was 1.390.13. The efﬁcacy and safety results were analyzed at 28
days. We measured the angiographic % diameter stenosis and histologic % area
stenosis, as well as neointimal area. The vascular healing process was evaluated
through the semi-quantitative scores of vascular injury, inﬂammation, ﬁbrin, and the
rate of endothelialized luminal surface.
Results: The tested SES (Test1, Test2) and the control SES and EES showed
similar restenosis results, while the control BMS showed signiﬁcantly higher
restenosis values. All the stents showed low values of vascular injury, as demon-
strated by low global injury (0.90.5) and inﬂammation (10.5) scores, without
differences between groups. On the contrary, some signs of delayed vascular
healing (directly related to the pharmacological effect) as lower endothelialization
rate and persistent ﬁbrin deposition, are signiﬁcantly worse in DES (no differences
between groups) than in BMS.acts/POSTER/Basic Science, Animal Models, and Cell Therapy B241
